AMRX News and Press, Amneal Pharmaceuticals Inc. Class A From 08/31/22

Amneal Pharmaceuticals ( NYSE: AMRX ) has submitted a New Drug Application to the US FDA for IPX203 , carbidopa/levodopa (CD/LD) extended-release capsules for Parkinson’s disease. The application is based on phase 3 data that showed more "good on" time compared ...

- IPX203 is a novel, extended-release oral formulation of carbidopa and levodopa that if approved, would offer patients more “Good On” time with fewer doses Amneal Pharmaceuticals, Inc. (NYSE: AMRX) today announced it has submitted a New Drug Application (N...

- Newly launched Congressional Domestic Pharmaceutical Manufacturing Caucus will work to ensure a resilient supply chain of key medicines manufactured in the U.S. to strengthen our national security, particularly in light of the pandemic and recent geopolitical conflicts Amn...

- Brings year-to-date generics launches to 16; on-track for 20-30 this year Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that it has received Abbreviated New Drug Application (ANDA) approval from the U.S. F...

Amneal Pharmaceuticals, Inc. (AMRX) Q2 2022 Earnings Conference Call August 5, 2022 08:30 ET Company Participants Anthony DiMeo - Senior Director of Investor Relations Chirag Patel - Co-Founder, Co-Chief Executive Officer, President & Director Chintu Patel - ...

Shares of Amneal Pharmaceuticals ( NYSE: AMRX ) fell as much as 11.7% to $3.06 in Friday morning trading, after the generic and specialty drugs maker slashed its FY 2022 adj. EPS and EBITDA guidance. AMRX stock had pared most of the losses and was trading 2.9% lower ...

Amneal Pharmaceuticals press release ( NYSE: AMRX ): Q2 Non-GAAP EPS of $0.19 in-line. Revenue of $559M (+4.5% Y/Y) beats by $24.56M . FY22 Guidance: Reaffirms Net revenue to $2.15B-$2.25B vs consensus of $2.17B; Adj EPS from prior $0.80-$0.85 to $0.65-$0.70 vs c...

‒ Q2 2022 Net Revenue of $559 million; GAAP Net Loss of $121 million; Diluted Loss per Share of $(0.80) ‒ ‒ Adjusted EBITDA (1) of $135 million; Adjusted Diluted EPS (1) of $0.19 ‒ ‒ Updates 2022 Adjusted EBITDA guidance ...

Amneal Pharmaceuticals ( NYSE: AMRX ) is scheduled to announce Q2 earnings results on Thursday, August 4th, before market open. The consensus EPS Estimate is $0.19 (-24.0% Y/Y) and the consensus Revenue Estimate is $534.44M (-0.1% Y/Y). Over the last 2 years, AMRX ha...

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its second quarter 2022 financial results on Friday August 5, 2022, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern T...